Bioprocessing Market Size, Share and Trends 2026 to 2035

Bioreactors: This segment dominated the bioprocessing market in 2025 with a 34.8% share, as biopharmaceutical companies will produce and sell more biologic products in the future and will also rely on the increased use of high-density cultures and the adoption of advanced automated modular production lines. The bioreactor solution is necessary for biopharmaceutical companies to manage their production operations effectively, achieve product consistency, enable scalability, and provide real-time data to accept, reject, and manage production processes, thereby improving efficiency across mammalian, microbial, and cell-based manufacturing.

The single-use bioreactors biopharmaceutical companies are the fastest-growing segment, using more single-use bioreactors in response to growing demand for flexible manufacturing and to minimize production downtime. Because single-use bioreactors can be easily changed and reused immediately, manufacturers are less likely to cross-contaminate or require a separate cleaning process. They can respond to the increased demand for smaller- to medium-scale single-use bioreactors for gene and cellular therapies.

Monoclonal Antibody Production: Monoclonal antibody production is the dominant application in the bioprocessing market in 2025 with a 38.6% share. The strong demand for monoclonal antibody products in oncology, autoimmune disease treatments, and chronic disease management has kept the monoclonal antibody segment growing. The mAb segment is aided by mature manufacturing processes, high yields from batch production, and standardized regulations governing monoclonal antibody production across all countries. Additionally, due to the heavy concentration of mAbs in biopharmaceutical companies' pipelines, monoclonal antibody production manufacturers are continually increasing their capacity and optimizing their production processes to support the production of large, cost-effective quantities of mAbs.

Cell & Gene Therapy: This segment is the fastest-growing, with a CAGR of 11.4%, driven by the rise of personalized regenerative medicine. These therapies are produced using specialized systems in the upstream manufacturing area, use viral vectors as delivery methods, and employ closed, single-use manufacturing processes, all of which have led to significant technology adoption. The rapid growth in cell and gene therapy and the trend toward decentralised production have resulted in continued rapid growth of this segment, as new companies develop flexible bioprocessing solutions that reduce the risk of contamination.

Large-scale Bioprocessing: This segment has emerged as the dominant capacity due to the demand for large-scale production of biologics such as monoclonal antibodies (mAbs), vaccines, and recombinant proteins. Established biopharmaceutical companies use large fermenters (up to 200,000 liters), extensive purification pipelines, and efficient bulk manufacturing techniques to meet this high demand. Furthermore, the combined weight of established infrastructure and economies of scale in large bioprocessing facilities has helped maintain this lead. The increasing global demand for biologics in both emerging and developed markets will continue to provide a means to expand the current capacity segment in the near future.

Small-Scale Bioprocessing: This segment is expected to be the fastest-growing, with a CAGR of 11.3%, driven by the trend towards personalization and low-volume production, as well as increasing interest in manufacturing for clinical trials. Small-scale bioprocessing enables rapid production of multiple batches, a low-cost process-development approach, and flexible manufacturing of therapy products, including gene and cell therapies and rare-disease products. Companies are using smaller, single-use systems and modular cleanrooms to accelerate research and development, as well as early-stage clinical trials, thereby enabling faster transfer from concept to clinical evaluation.

Pharmaceutical & Biotechnology Companies: This segment maintained its dominance in the bioprocessing space, with a 43.4% share, leveraging their manufacturing capabilities to build out their pipeline of therapeutic products, their ability to produce biologics in-house, and their ongoing commitment to improving biologics production processes. Pharmaceutical and biotechnology industries have large fleets of bioreactors, along with significant quantities of upstream and downstream technologies. These industries have also experienced an unprecedented increase in the number of biologics that have received FDA marketing approval, the development of next-generation biologics, and the utilization of increasingly diverse global manufacturing capabilities.

Contract Development & Manufacturing Organizations (CDMOs): As the fastest-growing end-user, with an 11.5% CAGR, contract development and manufacturing organizations (CDMOs) are significantly impacted as companies turn to them for flexibility, risk mitigation, and scalable, cost-effective manufacturing services. CDMOs are in demand for biomanufacturing services because emerging biotech companies rely on CDMOs to assist with developing their manufacturing processes, producing their final product for clinical trials, and ensuring regulatory compliance. CDMOs are also adopting module, single-use, and multi-disciplinary production systems, which further promote the rapid development of biomanufacturing.

The Asia Pacific market for bioprocessing is on track to become the industry's predominant growth area, with a 12.5% expected growth rate, as countries across the region continue to invest heavily in biologics production through government-sponsored incentives and the rapid advancement of modern manufacturing systems. National programs are accelerating this shift. China's 14th Five-Year Plan (2021–2025) prioritizes large-scale biomanufacturing and supports facility expansion through grants administered by the Ministry of Science and Technology. Japan's AMED Regenerative Medicine Program funds continuous bioprocessing innovation and cell-therapy scale-up, while South Korea's Bioeconomy 2025 Strategy invests in GMP infrastructure dedicated to monoclonal antibodies, viral vectors, and mRNA therapeutics.

Asia-Pacific countries are aggressively developing large-scale manufacturing capacity by widely adopting single-use bioreactors, continuous perfusion systems, and modular, flexible facility configurations that enable rapid adjustment of production volumes. These systems help manufacturers accelerate technology transfer, reduce contamination risk, and shorten the timeline between clinical-scale and commercial-scale production. India and Singapore, for example, have expanded biopharma industrial parks that integrate single-use workflows and real-time process analytics tools to support high-throughput manufacturing.

China Bioprocessing Market Trends

China is leading the Asia-Pacific in bioprocessing growth, making significant investments in the development of biologics and biosimilars, largely due to large State-backed financial support and a rapid pace of installing modern, flexible bioprocessing systems. By cooperating with global manufacturers, China can improve its processes and increase efficiency, while also developing a large R&D pipeline and constructing world-class biomanufacturing facilities. China has quickly become the driving force behind the Asia-Pacific bioprocessing industry's accelerated growth.

In June 2024, WuXi Biologics revealed plans to manufacture drug substance and products for Virogen Biotechnology at its new Chengdu microbial-production facility, and to produce a growth-hormone therapy for VISEN Pharmaceuticals, boosting microbial-manufacturing capacity in China.

With a strong emphasis on quality as mandated by the European Union and its vast pharmaceutical manufacturing facilities, Europe's bioprocessing market is growing rapidly. Europe is gradually implementing continuous processes, increasing efficiency through purification systems, and has begun utilizing digitalization to improve both productivity and sustainability. Europe has numerous innovation hubs across regions, including the UK, Germany, and Switzerland, where businesses partner closely with universities to develop biologics, cell therapies, and vaccines. Moreover, eco-friendly bioprocessing is a priority in European countries, and millions of euros are being invested to establish systems that generate less waste while maximizing energy use. Together with an experienced workforce and centralized regulatory processes, Europe has emerged as a technical advanced and stable bioprocessing centre.

Germany Bioprocessing Market Trends

Germany benefits from some of the world's best engineers and engineers of high-tech bioprocessing facilities, which are at the forefront of automation and machine learning. As a result, Germany has the most complete infrastructure and capability to classify and monitor the quality of bioprocessing facilities in Europe. Biotechnological production processes are being rapidly innovated through the integration of industry and universities, placing Germany as Europe's leading centre for bioprocessing.

The MEA is rapidly growing in its involvement in the bioprocessing market, as many of the country's governments are focused on developing a foundational biomanufacturing infrastructure. These governments are prioritising bioeconomy self-sufficiency, and investment will be made in innovation hubs, pilot-supported bioprocessing systems, and training for qualified personnel to prepare for the demand for bioprocessing innovation. Collaboration with global biomanufacturing companies is creating a knowledge platform to enhance technology transfer and ensure early adoption of modular, flexible production capabilities suited for transitioning into the local market. The demand for locally produced biologics and the establishment of fill/finish plants for vaccines and other cell-based therapies will help strengthen the position of MEA in a global landscape.

UAE Bioprocessing Market Trends

The United Arab Emirates (UAE) is actively leading the MEA region in the creation of biotechnology zones, innovative laboratory infrastructure, and partnerships to support new biomanufacturing technologies. The UAE is experiencing rapid growth in its innovation economy and has strong government backing, along with a growing number of innovation-focused facilities. The development of qualified scientific talent in biotechnology positions the UAE as the most robust innovator in bioprocessing across the MEA region.

In November 2025, Emirates Biotech unveiled its Embio product range, a new line of PLA (polylactic acid) biopolymers made in the UAE, offering recyclable, compostable alternatives to traditional plastics for packaging, fibers, paperboard, and 3D printing, to support a circular-economy transition.